



Swansea University
Prifysgol Abertawe



Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in:

Metabolism

Cronfa URL for this paper:

<http://cronfa.swan.ac.uk/Record/cronfa36625>

Paper:

Monnier, L., Colette, C. & Owens, D. Glucose variability: do we have to revisit the profusion of definitions to avoid confusion?. *Metabolism*

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

<http://www.swansea.ac.uk/library/researchsupport/ris-support/>

Glucose variability : Do we have to revisit the profusion of definitions to avoid confusion ?

L.Monnier¹, C. Colette¹, D Owens²

1 Institute of Clinical Research, University of Montpellier, Montpellier, France

2 Diabetes Research Group, Swansea University, Swansea, Wales, UK

Corresponding author: Louis Monnier

e-mail: louis.monnier@inserm.fr

Address:

Institute of Clinical Research
641 Avenue du Doyen Giraud
34093 Montpellier Cedex 5 (France)

Key words: Glucose variability, definitions, profusion, confusion

In this issue of Diabetes and Metabolism Lee et al [1] report the results of the impact of visit-to-visit variability in fasting plasma glucose (FPG) on the all-cause mortality of persons with type 2 diabetes. This retrospective analysis was a 2-year follow-up of 3569 persons attending a medical centre in Taiwan. The population was divided into groups according to whether visit-to-visit variations in FPG were low, labile (decreasing, fluctuating and increasing) or high. The authors conclude, that in persons with diabetes, the visit-to-visit variability of FPG referred to as 'long-term' glucose variability should be maintained as low as possible.

These results are in broad agreement with previous publications on the long-term deleterious impact of glucose variability. The retrospective studies of Muggeo [2], Kilpatrick [3] and others [4-7], complemented by a meta-analysis [8] have indicated that both in type 1 and type 2 diabetes, high FPG and HbA1c variability were associated with a greater risk for adverse clinical outcomes including either micro- or macro-vascular complications. However, the authors of the meta-analysis [8] noted that most studies suffered from inconsistencies in the definition of HbA1c variability considered as 'long-term' glycaemic variability. Also the impact of 'short-term' glycaemic variability, mainly within-day variability, on the development and progression of cardiovascular disease has never been established [9]. In an issue of Diabetes Care published in 2015, Hirsch [10] and Bergenstal [11] had a Point-Counterpoint debate. Hirsch argued that acute glucose fluctuations (within-day variability) are deleterious and should be a primary target [10]. Bergenstal however, argued that preferential consideration should be given to other markers than glycaemic variability [11]. The prospective FLAT-SUGAR trial [12] and the latest retrospective analysis of the clinical outcomes of the Diabetes Control and Complications Trial (DCCT) [9] failed to demonstrate any beneficial impact or influence of the 'short-term' (within-day glycaemic) variability on surrogate markers of cardiovascular disease [12] or on hard outcomes such as the risk for developing diabetic complications [9]. However, there arises the question as to whether the methodology used in both these analyses was appropriate. In the FLAT-SUGAR Study [12] reductions in the short-term glucose variability seen in the exenatide arm were not associated with changes in cardio-metabolic risk markers, due possibly to the use of insulin in both interventional arms capable of exerting an inhibitory effect upon the biological markers of inflammation and activation of the oxidative stress

[13]. In the retrospective analysis of the DCCT database, the short-term variability relied on quarterly 7-point discontinuous glucose profiles [9], although advocated in clinical studies evaluating therapeutic agents [14] it lacks the precision of continuous glucose monitoring (CGM) conducted over prolonged periods of time [15-20]. Therefore, it remains questionable whether self-monitoring of blood glucose on a single day at quarterly time-intervals can be expected to represent chronic glycaemic exposure (sustained hyperglycaemia) and its relationship to long-term diabetic complications. Presently, despite progress in continuous glucose monitoring (CGM) technology, we are still lacking affordable wearable devices, with no constraints, over prolonged periods of time such as several months or years. Consequently, it remains difficult to prove the existence of a clear relationship between either or both acute and long-term glycaemic variations and diabetes related complications.

In the meantime, many inconsistencies exist in the definition of glycaemic variability along with a profusion of surrogate markers which make it difficult to gain a clear insight into the potential causative role, in any, of acute exaggerated glycaemic fluctuations as risk factors of adverse clinical outcomes. However, in animal studies such 'dangerous waves' [21] have an adverse effect on vascular endothelial cells, due to the activation and perpetuation of oxidative stress, acknowledged as one of the key players in the development and progression of diabetic complications [22,23]. Currently some of the markers of glycaemic variability are devoted to the assessment of short-term glucose variability, standard deviation around the 24-h mean glucose value (SD) and coefficient of variation for glucose (CV) [24-26] while others are used for assessing the long-term variability ie HbA1c [8, 27]. However, other metrics used for assessing short-term glucose variability, are presently too complex for use by healthcare professionals and to be integrated into routine care. Included among these are i) the M-index described by Schlichtkrull in 1965 [28], ii) the MAGE (Mean Amplitude Glycemic Excursions) and the MODD (Mean of Daily Differences) that were developed in the early 1970s by Service and Molnar for assessing the within- and between- day glucose variability, respectively [29] and iii) others such as the MAG (Mean Absolute Glucose change per hour), CONGA (Continuous Overlapping Net Glycemic Action), ADRR (Average Daily Risk Rank) and the LBGI or HBGI (Low and High Blood Glucose Index) [24-26]. The LBGI and HBGI, are oriented towards

the risk prediction of adverse events such as hypoglycaemia or abnormal acute glucose peaks more than towards the specific assessment of glycaemic variability.

Characterising glycaemic variability includes either the measurement of glucose fluctuations or other parameters of glucose homeostasis over a given time-interval. This definition therefore covers two distinct types of measurements: i) Firstly, the within-and between-day glucose variability determined over short periods of time and ii) secondly, the visit-to-visit variability based on serial determinations of either fasting plasma glucose or HbA1c at regular monthly or quarterly time-intervals.

The traditional measure of dispersion and variability for normal distributed data uses the standard deviation (SD) and the coefficient of variation (CV) defined as $([SD/[mean\ value]] \times 100\%)$ in order to express the CV as a percentage. The daily within-day glucose variability, one of the most popular metrics of glycaemic variability, is referred to as the SD of glucose. However, the question remains whether the SD from a single day is a reliable reflection of the glycaemic variability. Consequently physicians should be encouraged to calculate the within-day variability, over an extended period of time such as over several consecutive days and then average the daily SDs, called the “mean of within-day daily glucose variability” [24, 25]. The relevance of this assessment should improve with increasing the duration of the monitoring period. However, if this period be extended beyond several days, especially when now using the new CGM devices, the within-day glucose variability needs to be referred to as ‘intermediate’, whilst also defining the time period involved, rather than as ‘short-term’ variability. Another method that can be used to estimate the daily glucose variability is to calculate the SD of averaged daily blood glucose profiles. Such a marker referred to as the “daily SD by average” provides an SD, which is usually smaller than the “mean of daily SD” [30], with the underestimation becoming more and more marked as soon as the synchrony of glucose patterns from day-to-day becomes more and more altered [24]. A large disparity between the mean of daily SD for glucose and the daily SD by average reflects a high between-day glucose variability.

An additional parameter of glucose variability can be computed by calculating the dispersion of the glucose data at a given time-point over several consecutive days. This type of computation, which is provided by the Flash monitoring system of the

Free style Libre, using the averaged glycaemic profile (AGP) over 14 days, reports the findings as IQRs (Interquartile Ranges). Large time point-to-time point variations in the IQRs indicates a loss of synchrony of glucose patterns from day-to-day, i.e. a high between-day variability (figure 1) in contrast to small IQR when between-day glucose variation is relatively small [24] (figure 1).

Although we have focused on SD and CV as the metrics of glucose variability and deliberately omitted the others that require mathematical skills, interpretation can still be somewhat difficult. Therefore, simplifying the findings appears a prerequisite in order that any healthcare provider can easily assess and interpret the degree of short-term glycaemic variability. According to our most recent research in this field, the CV for glucose seems to be the most appropriate index for assessing the mean daily within-day variability. As the SD for glucose is usually positively correlated with the mean glucose value, the CV renders the assessment of glycaemic variability independent of the mean glucose concentration, i.e. on one of the parameters that reflects the chronic glycaemic exposure. We have demonstrated that it can be a useful and simple tool for separating stable from labile diabetes by setting the cut-off value for the CV at 36% [31]. Previously, Hirsch had proposed as an ideal target for glycaemic variability an SD calculated from the following formula $SD \times 3$ mean glucose, i.e. a $CV < 33\%$, a value similar to that observed in our study [32].

Reverting to the second type of glycaemic variability, namely the long-term glycaemic variability, its assessment is usually based on visit-to-visit measurements of HbA1c or FPG which was used by Lee et al in the present issue of Diabetes Metabolism [1]. It is suggested that the word 'long-term variability' should be only applied to monthly measurements of glucose concentration at fasting or casual time-points or to quarterly determinations of HbA1c with the subsequent calculation of their SD or %CV. However, it should be emphasised that there is currently no 'standard' metrics, which partly explains the continued debate relating to the studies that have attempted to establish the relationships between the so-called short-term [9] or long-term glycaemic variability [8] and clinical outcomes. As indicated in a recent publication, the long-term variability is probably an "umbrella" for distinct glycaemic disorders [33]. It is highly likely that the short-term variability, i.e. the true diabetes lability, is mainly dependent on patient's metabolic intrinsic factors whilst the long-

term variability is more influenced by many external confounding factors such as poor compliance to dietary and pharmacological treatments.

Whilst bringing all these observations and hypotheses together and returning to the key words of our editorial: “definition, profusion and confusion” we currently recommend to limit the term “glycaemic variability” to the “mean of within-day daily glucose variability” assessed from the mean CV for glucose by averaging each daily value over a period of several consecutive days. Utilising a threshold of 36% for the CV allows one to discern between stable from labile diabetes [31]. An important fact is that unstable diabetes with exaggerated acute glucose fluctuation is associated with, and perhaps responsible for an increased risk of hypoglycaemic episodes [31,34,35,36].

In conclusion, the main objectives in the management of diabetes need to include the concomitant reduction of both the chronic “ambient” hyperglycaemia and the acute daily glucose fluctuations. The availability of newly marketed antidiabetic medications such as the class of incretin agents e.g. DPP4 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, SGLT2 inhibitors and the long-acting insulin preparations with flat profiles can help to avoid excessive glucose variability [12,37,38]. Finally, we expect that, in the near future, standards of medical care in diabetes will integrate the glycaemic variability (for instance a CV \leq 36%) as a glycaemic target besides the HbA1c \leq 7% and the threshold of alert for hypoglycaemia (<70 mg/dL; 3.9 mmol/l) [39] (figure 2).

Disclosure of interest

The authors declare that they have no competing interest with the content of this editorial.

References

- [1] Lee C-H, Sheu WH-H, Lee I-T, Lin S-Y, Liang W-M, Wang J-S, et al. Trajectory of fasting plasma glucose variability and mortality in diabetes: a retrospective cohort study. *Diabetes Metab* 2017 [inpress]
- [2] Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. *Diabetes Care* 2000;23:45-50
- [3] Kilpatrick ES, Rigby AS, Atkin SL. A1c variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. *Diabetes Care* 2008;31:2198-2202
- [4] Hietala K, Wadén, Forsblom C et al, Finn Diane Study Group. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. *Diabetologia* 2013;56:737-745
- [5] Luk AO, Ma RC, Lau ES et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. *Diabetes Metab Res Rev* 2013;29:384-390
- [6] Takao T, Matsuyama Y, Yanagisawa H, Kibuchi M, Kawazu S. Association between A1c variability and mortality in patients with type 2 diabetes. *J Diabetes Complications* 2014;28:494-499
- [7] Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. *Diabetes Care* 2014;37:2359-2365
- [8] Gorst C, Kwak CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. *Diabetes Care* 2015;38:2354-2369
- [9] Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, et al, for the DCCT/EDIC Research Group. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial. *Diabetes Care* 2017;40:777-783
- [10] Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! *Diabetes Care* 2015;38:1610-1614

- [11] Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers? *Diabetes Care* 2015;38:1615-1621
- [12] FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. *Diabetes Care* 2016;39:973-981
- [13] Monnier L, Colette C, Mas E, Michel F, Cristol J-P, Boegner C, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. *Diabetologia* 2010;53:562-571
- [14] Schnell O, Hanefeld M, Monnier L. Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials. *J Diabetes Sci Technol* 2014;8:609-614
- [15] Rodbard D. Continuous glucose monitoring. A review of successes, challenges and opportunities. *Diabetes Technol Ther* 2016;18 (Suppl 2): S2-3-S2-13
- [16] Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B et al. Role of continuous glucose monitoring in clinical trials: recommendations on reporting. *Diabetes Technol Ther* 2017;19:391-399
- [17] Garg SK, Akturk HK. Flash glucose monitoring: The future is here. *Diabetes Technol Ther* 2017;19 (Suppl 2):S-1-S-3
- [18] Bailey TS. Clinical implications of accuracy measurements of continuous glucose sensors. *Diabetes Technol Ther* 2017;19 (Suppl 2): S-51-S-54
- [19] Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. *Diabetes Technol Ther* 2015;17:787-794
- [20] Slattery D, Choudhary P. Clinical use of continuous glucose monitoring in adults with type 1 diabetes. *Diabetes Technol Ther* 2017;19 (Suppl 2):S-55-S-61
- [21] Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. *Diabetologia* 2003;46 (Suppl 1):M9-M16

- [22] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001;414:813-820
- [23] Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* 2005;54:1615-1625
- [24] Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. *Diabetes Technol Ther* 2009;11:551-565
- [25] Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. *Diabetes Technol Ther* 2009;11 (Suppl 1):S-55-S-67
- [26] Kovatchev BP. Metrics for glycaemic control-from HbA1c to continuous glucose monitoring. *Nat Rev Endocr* 2017;13:425-436
- [27] Sacks DB. Measurement of hemoglobin A1c: a new twist on the path to harmony. *Diabetes Care* 2012; 35:2674-2680
- [28] Schlichtkrull J, Munch O, Jersild M. The M-value, an index of blood sugar control in diabetics. *Acta Med Scand* 1965;177:95-102
- [29] Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. *Diabetes* 1970 ;19 :644-655
- [30] Bajaj HS, Venn K, Ye C, Patrick A, Kalra S, Khandwala H, et al. Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study). *Diabetes Care* 2017;40:194-200
- [31] Monnier L, Colette C, Wojtuszczyzn A, Dejager S, Renard E, Molinari N, et al. Toward defining the threshold between low and high glucose variability in diabetes. *Diabetes Care* 2017;40:832-838
- [32] Hirsch IB. Glycemic variability: it's not just about A1c anymore! *Diabetes Technol Ther* 2005;7:780-783
- [33] Noyes JD, Soto-Pedre E, Donnelly LA, Pearson ER. Characteristics of people with high visit-to-visit glycaemic variability in type 2 diabetes. *Diabet Med* 2017:DOI:10.1111/dme.13435
- [34] Monnier L, Wojtuszczyzn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. *Diabetes Technol Ther* 2011;13:813-818

- [35] Monnier L, Colette C, Dejager S, Owens DR. Near normal HbA1c with stable glucose homeostasis : the ultimate target/aim of diabetes therapy. *Rev Endocr Metab Disord* 2016;17:91-101
- [36] Kovatchev B, Cobelli C. Glucose variability: Timing, risk analysis, and relationship to hypoglycemia in diabetes. *Diabetes Care* 2016;39:502-510
- [37] Zinman B, Marso SP, Poulter NR, Emerson SS, Peiber TR, Pratley RE, on behalf of the DEVOTE Study Group. Day-to-day fasting glycemic variability in DEVOTE: association with severe hypoglycaemia and cardiovascular outcomes. *Diabetologia* 2017:DOI:10.100
- [38] King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Visboll T. A fixed ratio combination of insulin degludec and liraglutide (IDegLira) reduces glycemic fluctuation and brings more patients with type 2 diabetes within blood glucose target ranges. *Diabetes Technol Ther* 2017;19:255-264
- [39] American Diabetes Association. Glycemic targets 2017;40 (suppl 1):S48-S56

Legends of figures

Figure 1: Averaged glucose profiles (AGPs) from two patients with the same averaged median interstitial glucose value (165 mg, black dotted line). The displayed glucose profiles and medians of glucose (black solid lines) are 14 days of CGM data. Shaded dark areas correspond to either IQRs (Interquartile ranges) or 10th-90th percentiles.

The upper panel is the illustration of a patient in whom the synchrony of glucose patterns is relatively preserved, i.e. with a small between-day glucose variability characterized by small IQRs and small time point-to-point IQR variations.

The bottom panel is the illustration of a patient with a high loss of synchrony from day-to-day in glucose patterns, i.e. a high between-day glucose variability (high time-to-time IQR variation)

Figure 2: Glycaemic targets recommended for HbA1c and glucose alert threshold for hypoglycaemia (reference 39) and suggested for glycaemic variability expressed as %CV (reference 31).




Figure 1




Figure 2